Detalimogene interim data supports 2027 U.S. approval push
Detalimogene, a non-viral gene therapy for BCG-unresponsive NMIBC, is advancing toward a 2027 U.S. approval supported by interim efficacy, safety and ease-of-use data.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.